Kyle Diamantas leads trader consensus at 47% as the acting FDA commissioner following Marty Makary’s May 2026 departure after roughly 13 months in the role. Diamantas’s prior service as deputy commissioner for human foods, his regulatory background, and reported ties to the Trump family position him as an immediate continuity choice amid ongoing agency leadership transitions. Sara Brenner, who served earlier as acting and principal deputy commissioner before moving to an HHS senior counselor role under Robert F. Kennedy Jr., holds 17% on the strength of her extensive FDA experience. Stephen Hahn, Brett Giroir, and Grace Graham trail as longer-shot options discussed in reporting. The 21% probability assigned to no announcement by December 31 reflects Senate confirmation hurdles, including qualification preferences and policy litmus tests, plus the compressed timeline before the midterms.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoKyle Diamantas 36%
No announcement by December 31 20.6%
Sara Brenner 18.0%
Brett Giroir 9.9%
$12,475 Vol.
$12,475 Vol.
31 dic 2026
Kyle Diamantas
42%
Stephen Hahn
5%
Brett Giroir
10%
Grace Graham
7%
Sara Brenner
17%
No announcement by December 31
21%
Kyle Diamantas 36%
No announcement by December 31 20.6%
Sara Brenner 18.0%
Brett Giroir 9.9%
$12,475 Vol.
$12,475 Vol.
31 dic 2026
Kyle Diamantas
$2,497 Vol.
42%
Stephen Hahn
$1,516 Vol.
5%
Brett Giroir
$2,435 Vol.
10%
Grace Graham
$3,416 Vol.
7%
Sara Brenner
$2,021 Vol.
17%
No announcement by December 31
$590 Vol.
21%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas leads trader consensus at 47% as the acting FDA commissioner following Marty Makary’s May 2026 departure after roughly 13 months in the role. Diamantas’s prior service as deputy commissioner for human foods, his regulatory background, and reported ties to the Trump family position him as an immediate continuity choice amid ongoing agency leadership transitions. Sara Brenner, who served earlier as acting and principal deputy commissioner before moving to an HHS senior counselor role under Robert F. Kennedy Jr., holds 17% on the strength of her extensive FDA experience. Stephen Hahn, Brett Giroir, and Grace Graham trail as longer-shot options discussed in reporting. The 21% probability assigned to no announcement by December 31 reflects Senate confirmation hurdles, including qualification preferences and policy litmus tests, plus the compressed timeline before the midterms.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Mercado abierto: May 12, 2026, 7:59 PM ET
Volumen
$12,475Fecha de finalización
31 dic 2026Mercado abierto
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Kyle Diamantas leads trader consensus at 47% as the acting FDA commissioner following Marty Makary’s May 2026 departure after roughly 13 months in the role. Diamantas’s prior service as deputy commissioner for human foods, his regulatory background, and reported ties to the Trump family position him as an immediate continuity choice amid ongoing agency leadership transitions. Sara Brenner, who served earlier as acting and principal deputy commissioner before moving to an HHS senior counselor role under Robert F. Kennedy Jr., holds 17% on the strength of her extensive FDA experience. Stephen Hahn, Brett Giroir, and Grace Graham trail as longer-shot options discussed in reporting. The 21% probability assigned to no announcement by December 31 reflects Senate confirmation hurdles, including qualification preferences and policy litmus tests, plus the compressed timeline before the midterms.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
Volumen
$12,475Fecha de finalización
31 dic 2026Mercado abierto
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Kyle Diamantas leads trader consensus at 47% as the acting FDA commissioner following Marty Makary’s May 2026 departure after roughly 13 months in the role. Diamantas’s prior service as deputy commissioner for human foods, his regulatory background, and reported ties to the Trump family position him as an immediate continuity choice amid ongoing agency leadership transitions. Sara Brenner, who served earlier as acting and principal deputy commissioner before moving to an HHS senior counselor role under Robert F. Kennedy Jr., holds 17% on the strength of her extensive FDA experience. Stephen Hahn, Brett Giroir, and Grace Graham trail as longer-shot options discussed in reporting. The 21% probability assigned to no announcement by December 31 reflects Senate confirmation hurdles, including qualification preferences and policy litmus tests, plus the compressed timeline before the midterms.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes